Neurocrine Biosciences (NBIX) Competitors $138.61 +1.92 (+1.40%) (As of 12:29 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NBIX vs. ALNY, BIIB, UTHR, INCY, BMRN, EXAS, EXEL, RGEN, MDGL, and HALOShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. Neurocrine Biosciences vs. Alnylam Pharmaceuticals Biogen United Therapeutics Incyte BioMarin Pharmaceutical Exact Sciences Exelixis Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Neurocrine Biosciences (NASDAQ:NBIX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Which has higher valuation & earnings, NBIX or ALNY? Neurocrine Biosciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurocrine Biosciences$2.24B6.17$249.70M$3.7336.65Alnylam Pharmaceuticals$2.09B15.18-$440.24M-$2.62-94.11 Does the media favor NBIX or ALNY? In the previous week, Neurocrine Biosciences had 14 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 29 mentions for Neurocrine Biosciences and 15 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.99 beat Neurocrine Biosciences' score of 0.97 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 15 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend NBIX or ALNY? Neurocrine Biosciences presently has a consensus price target of $166.00, indicating a potential upside of 21.44%. Alnylam Pharmaceuticals has a consensus price target of $298.09, indicating a potential upside of 20.89%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Neurocrine Biosciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurocrine Biosciences 0 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.83Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.71 Is NBIX or ALNY more profitable? Neurocrine Biosciences has a net margin of 17.21% compared to Alnylam Pharmaceuticals' net margin of -15.86%. Neurocrine Biosciences' return on equity of 15.68% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Neurocrine Biosciences17.21% 15.68% 11.38% Alnylam Pharmaceuticals -15.86%N/A -8.38% Does the MarketBeat Community believe in NBIX or ALNY? Alnylam Pharmaceuticals received 120 more outperform votes than Neurocrine Biosciences when rated by MarketBeat users. However, 77.45% of users gave Neurocrine Biosciences an outperform vote while only 76.14% of users gave Alnylam Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNeurocrine BiosciencesOutperform Votes101377.45% Underperform Votes29522.55% Alnylam PharmaceuticalsOutperform Votes113376.14% Underperform Votes35523.86% Which has more volatility and risk, NBIX or ALNY? Neurocrine Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Do institutionals & insiders hold more shares of NBIX or ALNY? 92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryNeurocrine Biosciences beats Alnylam Pharmaceuticals on 14 of the 19 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.84B$2.98B$5.14B$9.31BDividend YieldN/A1.85%4.81%4.06%P/E Ratio36.6546.24135.3117.54Price / Sales6.17420.221,260.42139.42Price / Cash49.72182.1340.5837.95Price / Book6.023.924.884.92Net Income$249.70M-$42.03M$118.89M$225.78M7 Day Performance6.61%-3.37%15.96%-1.56%1 Month Performance16.21%7.95%15.87%6.68%1 Year Performance13.98%21.00%34.78%22.48% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.8867 of 5 stars$138.61+1.4%$166.00+19.8%+13.7%$14.03B$2.24B37.161,400Analyst ForecastPositive NewsALNYAlnylam Pharmaceuticals4.5509 of 5 stars$246.53+0.4%$298.09+20.9%+33.1%$31.80B$1.83B-93.682,100Short Interest ↓BIIBBiogen4.7389 of 5 stars$151.25+0.8%$245.32+62.2%-39.3%$22.04B$9.61B13.697,570Analyst DowngradeUTHRUnited Therapeutics4.7089 of 5 stars$370.95+2.5%$370.860.0%+54.1%$16.56B$2.76B16.221,168Positive NewsINCYIncyte4.4745 of 5 stars$70.38+2.7%$76.13+8.2%+11.4%$13.56B$4.08B489.642,524Analyst ForecastBMRNBioMarin Pharmaceutical4.9847 of 5 stars$66.07+0.1%$94.20+42.6%-30.8%$12.59B$2.75B39.533,401Positive NewsEXASExact Sciences4.6099 of 5 stars$60.48-1.3%$72.94+20.6%-8.4%$11.19B$2.50B-52.356,600EXELExelixis4.5588 of 5 stars$36.01+2.8%$31.47-12.6%+48.2%$10.28B$2.08B22.461,310Analyst DowngradeShort Interest ↑RGENRepligen3.7688 of 5 stars$160.24+2.4%$190.25+18.7%-12.7%$8.98B$639.92M-422.731,783Analyst ForecastAnalyst RevisionMDGLMadrigal Pharmaceuticals4.3004 of 5 stars$310.87+2.1%$347.33+11.7%+29.1%$6.78BN/A-12.1490Positive NewsHALOHalozyme Therapeutics4.9931 of 5 stars$48.39+0.8%$61.11+26.3%+24.6%$6.16B$947.36M15.98390Analyst ForecastPositive News Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Incyte Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Exelixis Competitors Repligen Competitors Madrigal Pharmaceuticals Competitors Halozyme Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NBIX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
